Biopharmaceutical firm Biogen Idec Inc., maker of the recently-withdrawn multiple sclerosis drug Tysabri, said Executive Vice President and General Counsel Thomas J. Bucknum has resigned from the company, effective immediately. Bucknum's sudden departure comes amid a regulatory inquiry into his sale of Biogen stock the same day the company says it learned of patient illnesses that led to Tysabri's withdrawal from the market.
March 11, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Company DescriptionA prominent boutique AV rated Education Law firm located in Westbury, New York. Our firm specializes in education law, sp...
Seeking motivated and skilled litigation attorney to join our dynamic defense litigation firm. Role Involves:Conducting thorough research.Ha...
DEPUTY PORT ATTORNEY III Oakland, CA Salary: $17,294 - $21,419/month, 37.5-hr work week Your Port. Your Community. Your Career. Whe...